In the October issue of Biotechnology Focus, Cato Research’s very own Chief Financial Officer and Principal of Cato BioVentures, Daniel Pharand, discusses the recent shift and latest trends in financing within the biotechnology industry. “There have been a number of trends in the biotech funding world since its last bubble and bust in the early 90’s. Those were the trends that attracted funding from venture and angel investors…These days these trends or buzz words are not sufficient to attract money anymore.”
The reality has changed and new financing trends have begun to emerge. From Project Base Financing to the conversion of sweat equity by service providers, Biotechs will be compelled to consider these creative and innovative financial tools while CROs that embrace the new opportunities that emanate from these will have a great role to play in the success of those models.
You can find the full article online here.
- US Biotech Market Expected to Grow 7% Annually Through 2013 – Marketwire (press release) (news.google.com)
- PwC: Biotechs must adapt to survive in a harsh new world (fiercebiotech.com)
- Vendor Selection – All that Glitters is Not Gold (ask-cato.com)